CSSPF: AI 评分 47/100 — AI 分析 (4月 2026)

NIOX Group Plc specializes in point-of-care fractional exhaled nitric oxide (FeNo) diagnosis and management products. Their flagship product, NIOX VERO, aids in the non-invasive measurement of nitric oxide in human breath, crucial for asthma management.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

NIOX Group Plc, a UK-based diagnostics firm, provides point-of-care FeNo testing solutions with its NIOX VERO system. Focused on asthma management, the company leverages its portable technology to offer non-invasive nitric oxide measurement, serving a global market within the medical devices industry.

CSSPF是做什么的？

NIOX Group Plc, formerly known as Circassia Group Plc, was founded in 2006 and is headquartered in Oxford, United Kingdom. The company operates as a diagnostics and management entity, specializing in point-of-care fractional exhaled nitric oxide (FeNo) diagnosis and management products. Its core product, NIOX VERO, is a portable system designed for the non-invasive measurement of nitric oxide levels in human breath. This measurement is crucial in the diagnosis and management of asthma, aiding healthcare professionals in assessing airway inflammation. NIOX Group Plc focuses on providing tools that enable more effective and personalized asthma management. The NIOX VERO system is used by healthcare providers worldwide to monitor and manage patients with allergic airway inflammation. The company's technology helps clinicians optimize treatment plans and improve patient outcomes by providing real-time insights into airway inflammation. NIOX Group Plc operates globally, distributing its products to various healthcare markets. The company changed its name to NIOX Group Plc in September 2022, reflecting its strategic focus on nitric oxide-based diagnostics.

CSSPF的投资论点是什么？

NIOX Group Plc presents an interesting investment case within the medical devices sector. The company's focus on FeNo testing for asthma management positions it in a niche market with potential for growth, driven by increasing asthma prevalence and the need for personalized treatment approaches. With a gross margin of 71.1% and a profit margin of 11.3%, NIOX demonstrates strong profitability. Key catalysts include expanding the adoption of NIOX VERO in primary care settings and securing reimbursement approvals in new markets. However, investors should be aware of the company's debt-to-equity ratio of 1.86 and the risks associated with operating in a competitive medical device market. The company's ROE is 6.7%.

CSSPF在哪个行业运营？

NIOX Group Plc operates within the medical devices industry, specifically focusing on diagnostic tools for respiratory conditions. The global medical devices market is projected to reach $600 billion by 2028, driven by technological advancements and an aging population. The asthma diagnostics segment is experiencing growth due to increasing prevalence of asthma and the demand for personalized medicine. NIOX faces competition from established players in respiratory diagnostics, but its focus on point-of-care FeNo testing provides a unique value proposition.

Medical Devices

Healthcare

CSSPF有哪些增长机遇？

Expanding NIOX VERO adoption in primary care: NIOX Group Plc has the opportunity to increase the adoption of NIOX VERO in primary care settings. This would involve educating primary care physicians about the benefits of FeNo testing and integrating NIOX VERO into their diagnostic workflows. The market size for primary care asthma diagnostics is estimated at $500 million, with potential for significant growth over the next 3-5 years.
Securing reimbursement approvals in new markets: NIOX Group Plc can drive growth by securing reimbursement approvals for NIOX VERO in new geographic markets. This would make the product more accessible to patients and healthcare providers. The global market for asthma diagnostics is estimated at $1.5 billion, with significant opportunities in emerging markets over the next 2-3 years.
Developing new applications for FeNo technology: NIOX Group Plc can leverage its expertise in FeNo technology to develop new applications beyond asthma management. This could include using FeNo testing to diagnose and monitor other respiratory conditions, such as COPD and allergic rhinitis. The market size for novel respiratory diagnostics is estimated at $300 million, with potential for growth over the next 5 years.
Partnering with pharmaceutical companies: NIOX Group Plc can collaborate with pharmaceutical companies to integrate NIOX VERO into clinical trials and patient management programs for asthma medications. This would provide valuable data on treatment response and help optimize patient outcomes. The market for companion diagnostics in asthma is estimated at $200 million, with potential for growth over the next 3 years.
Enhancing the NIOX VERO platform with digital health solutions: NIOX Group Plc can enhance the NIOX VERO platform by integrating it with digital health solutions, such as mobile apps and cloud-based data analytics. This would provide patients and healthcare providers with real-time insights into asthma control and enable more personalized treatment plans. The market for digital health solutions in respiratory care is estimated at $400 million, with potential for growth over the next 5 years.

Market Cap of $0.38B reflects the company's current valuation in the medical device market.
Gross Margin of 71.1% indicates strong pricing power and efficient cost management in its diagnostic product line.
Profit Margin of 11.3% demonstrates the company's ability to convert revenue into profit after all expenses.
Return on Equity (ROE) of 6.7% shows the return generated for shareholders on their equity investment.
Beta of -0.22 suggests the stock is less volatile than the overall market, potentially offering stability in uncertain times.

CSSPF提供哪些产品和服务？

Develops and markets the NIOX VERO system for point-of-care FeNo testing.
Provides a non-invasive method for measuring nitric oxide in human breath.
Offers diagnostic tools for asthma management.
Supports healthcare professionals in assessing airway inflammation.
Helps clinicians optimize treatment plans for asthma patients.
Distributes its products globally to various healthcare markets.
Focuses on personalized asthma management through its technology.

CSSPF如何赚钱？

Sells NIOX VERO systems to hospitals, clinics, and physician offices.
Generates revenue from the sale of consumables used with the NIOX VERO system.
Provides service and support for its installed base of NIOX VERO systems.
Pursues reimbursement approvals to ensure product accessibility.

Hospitals and clinics that treat asthma patients.
Physician offices specializing in respiratory care.
Healthcare providers managing patients with allergic airway inflammation.
Research institutions conducting studies on asthma and respiratory diseases.

Proprietary FeNo testing technology with patent protection.
Established market presence in the asthma diagnostics segment.
Strong relationships with key opinion leaders in respiratory medicine.
High switching costs for customers due to established workflows and training.

什么因素可能推动CSSPF股价上涨？

Upcoming: Publication of clinical trial results demonstrating the efficacy of NIOX VERO in guiding asthma treatment decisions (expected Q4 2026).
Ongoing: Expansion of NIOX VERO adoption in primary care settings through physician education and training programs.
Ongoing: Securing reimbursement approvals for NIOX VERO in key European markets.
Upcoming: Launch of a new digital health solution integrated with the NIOX VERO platform (expected Q2 2027).

CSSPF的主要风险是什么？

Potential: Competition from established players in the respiratory diagnostics market.
Potential: Technological obsolescence of the NIOX VERO system.
Ongoing: Changes in reimbursement policies affecting the adoption of FeNo testing.
Potential: Economic downturn impacting healthcare spending and diagnostic testing volumes.
Ongoing: High debt-to-equity ratio poses financial risk.

CSSPF的核心优势是什么？

Proprietary NIOX VERO technology.
Established market presence in FeNo testing.
High gross margins.
Global distribution network.

CSSPF的劣势是什么？

High debt-to-equity ratio.
Limited product portfolio.
Dependence on asthma diagnostics market.
Small company size limits resources.

CSSPF有哪些机遇？

Expanding into primary care settings.
Securing reimbursement approvals in new markets.
Developing new applications for FeNo technology.
Partnering with pharmaceutical companies.

CSSPF面临哪些威胁？

Competition from established players in respiratory diagnostics.
Technological obsolescence.
Changes in reimbursement policies.
Economic downturn affecting healthcare spending.

CSSPF的竞争对手是谁？

Pulmatrix Inc — Focuses on inhaled therapies for respiratory diseases. — (PHD)
MeiraGTx Holdings plc — Develops gene therapies for ocular, neurological, and other diseases. — (MGTX)
Alpine Immune Sciences Inc — Focuses on developing protein-based immunotherapies. — (ALPN)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Jonathan Emms
Headquarters: Oxford, GB
Employees: 91
Founded: 2020

AI Insight

AI analysis pending for CSSPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does NIOX Group Plc do?

NIOX Group Plc specializes in the development and commercialization of point-of-care diagnostic tools for asthma management. Its flagship product, NIOX VERO, is a portable system that measures fractional exhaled nitric oxide (FeNo) levels in human breath. This non-invasive test helps healthcare professionals assess airway inflammation in asthma patients, enabling more personalized treatment decisions. The company's business model revolves around selling NIOX VERO systems and related consumables to hospitals, clinics, and physician offices worldwide.

What do analysts say about CSSPF stock?

AI analysis is pending for CSSPF stock. Generally, analysts covering medical device companies focus on factors such as revenue growth, gross margins, profitability, and market share. Key valuation metrics include price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-EBITDA (EV/EBITDA). Growth considerations include the company's ability to expand into new markets, develop innovative products, and secure reimbursement approvals. Analyst ratings and price targets reflect their expectations for the stock's future performance.

What are the main risks for CSSPF?

NIOX Group Plc faces several risks, including competition from established players in the respiratory diagnostics market, the potential for technological obsolescence of its NIOX VERO system, and changes in reimbursement policies that could affect the adoption of FeNo testing. The company's high debt-to-equity ratio also poses a financial risk. Additionally, an economic downturn could impact healthcare spending and diagnostic testing volumes. Investors should carefully consider these risks before investing in CSSPF.